25 May 2013
Keywords: tarceva, improves, pfs, advanced, nsclc, usa, osi
Article | 18 May 2009
The USA's OSI Pharmaceuticals presented positive, detailed results from the Phase III SATURN study of Tarceva (erlotinib) as a single ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
18 May 2009
19 May 2009
24 May 2013
© 2013 thepharmaletter.com